Petra Zieglmayer

Petra Zieglmayer

Auto-generated profile, based on publicly available information

Petra Zieglmayer

Karl Landsteiner University of Health Sciences Krems Austria

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2017 in Allergy
Verified
Journal Article
Open access
PDF file
OPO. Pfaar
O. Pfaar
MCM. A. Calderon
M. A. Calderon
CAC. P. Andrews
C. P. Andrews
EAE. Angjeli
E. Angjeli
KBK. C. Bergmann
K. C. Bergmann
PDPascal Demoly
Pascal Demoly
Background: Allergen exposure chambers (AECs) are clinical facilities allowing for controlled exposure of subjects to allergens in an enclosed environment. AECs have contributed towards characterizing the pathophysiology of respiratory allergic diseases and the pharmacological properties of new therapies. In addition, they are complementary to and offer some advantages over traditional multicentre field trials for evaluation of novel therapeutics. To date, AEC studies conducted have been monocentric and have followed protocols unique to each centre. Because there are technical differences among AECs, it may be necessary to define parameters to standardize the AECs so that studies may be extrapolated for driving basic immunological research and for marketing authorization purposes by regulatory authorities.Methods: For this task force initiative of the European Academy of Allergy and Clinical Immunology (EAACI), experts from academia and regulatory agencies met with chamber operators to list technical, clinical and regulatory unmet needs as well as the prerequisites for clinical validation.Results: The latter covered the validation process, standardization of challenges and outcomes, intra‐ and interchamber variability and reproducibility, in addition to comparability with field trials and specifics of paediatric trials and regulatory issues.Conclusion: This EAACI Position Paper aims to harmonize current concepts in AECs and to project unmet needs with the intent to enhance progress towards use of these facilities in determining safety and efficacy of new therapeutics in the future.

24 November 2017 in Allergy
Verified
Journal Article
Open access
PDF file
OPO. Pfaar
O. Pfaar
SBS. Bonini
S. Bonini
VCV. Cardona
V. Cardona
PDPascal Demoly
Pascal Demoly
TJT. Jakob
T. Jakob
TGthe FASIT group
the FASIT group
The Future of the Allergists and Specific Immunotherapy (FASIT) workshop provides a regular platform for global experts from academia, allergy clinics, regulatory authorities and industry to review developments in the field of allergen immunotherapy (AIT). The most recent meeting, held in February 2017, had two main themes: advances in AIT and hot topics in AIT from the regulatory point of view. The first theme covered opportunities for personalized AIT, advances in adjuvants and delivery systems, and the development of new molecules and future vaccines for AIT. Key topics in the second part of the meeting were the effects of the enactment of European Directive 2001/83 on the availability of allergens for therapy and diagnosis across the EU, the challenges of conducting Phase 3 studies in the field, the future role of allergen exposure chambers in AIT studies and specific considerations in performing AIT studies in the paediatric population. Finally, the group highlighted the forthcoming EAACI guidelines and their particular importance for the standardization of practice in the treatment of allergies. This review presents a comprehensive insight into those panel discussions and highlights unmet needs and also possible solutions to them for the future.

24 May 2021 in Allergy
Verified
Journal Article
Open access
PDF file
OPO Pfaar
O Pfaar
KBK C Bergmann
K C Bergmann
SBSs Bonini
Ss Bonini
ECE Compalati
E Compalati
NDN Domis
N Domis
PZP Zieglmayer
P Zieglmayer
Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non‐allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma).In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose‐finding Phase II trials is emphasized. Although methodologically insulated from the variability of natural pollen exposure, chamber models remain confined to supporting secondary, rather than primary, endpoints in Phase III registration trials. The need for further validation in comparison with field exposure is clearly mandated.On this basis, the European Academy of Allergy and Clinical Immunology (EAACI) initiated a Task Force in 2015 charged to gain a better understanding of how AECs can generate knowledge about respiratory allergies and can contribute to the clinical development of treatments.Researchers working with AECs worldwide were asked to provide technical information in eight sections: (i) dimensions and structure of the AEC, (ii) AEC staff, (iii) airflow, air processing, and operating conditions, (iv) particle dispersal, (v) pollen/particle counting, (vi) safety and non‐contamination measures, (vii) procedures for symptom assessments, (viii) tested allergens/substances and validation procedures. On this basis, a minimal set of technical requirements for AECs applied to the field of allergology is proposed.

17 April 2008 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
PZPetra Zieglmayer
Petra Zieglmayer
RZRené Zieglmayer
René Zieglmayer
PBPhilippe Bareille
Philippe Bareille
VRVicki Rousell
Vicki Rousell
ESEmma Salmon
Emma Salmon
FHFriedrich Horak
Friedrich Horak
(2008). Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Current Medical Research and Opinion: Vol. 24, No. 6, pp. 1833-1840. doi: 10.1185/03007990802155792

1 January 2021 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
ESEszter Sarzsinszky
Eszter Sarzsinszky
CLChristian Lupinek
Christian Lupinek
SVSusanne Vrtala
Susanne Vrtala
HHHuey-Jy Huang
Huey-Jy Huang
GHGerhard Hofer
Gerhard Hofer
RVRudolf Valenta
Rudolf Valenta
Sarzsinszky E, et al. Allergy Asthma Immunol Res. 2021 Jan;13(1):154-163. https://doi.org/10.4168/aair.2021.13.1.154

29 July 2020 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
OPO. Pfaar
O. Pfaar
PZP. Zieglmayer
P. Zieglmayer
Allergen exposure chambers (AECs) have been developed for controlled allergen challenges of allergic patients mimicking natural exposure. As such, these facilities have been utilized e.g., for proof of concept, dose finding or the demonstration of onset of action and treatment effect sizes of antiallergic medication. Moreover, clinical effects of and immunological mechanisms in allergen immunotherapy (AIT) have been investigated in AECs. In Europe AIT products have to fulfill regulatory requirements for obtaining market authorization through Phase I to III clinical trials. Multiple Phase II (dose-range-finding or proof-of-concept) trials on AIT products have been performed in AECs. However, they are not accepted by regulatory bodies for pivotal (Phase III) trials and a more thorough technical and clinical validation is requested. Recently, a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI) has outlined unmet needs in further development of AECs. The following review aims to address some of these needs on the basis of recently published data in the first part, whereas the second part overviews published examples of most relevant Phase II trials in AIT performed in AEC facilities.